Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06371157
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-17
First Post:
2024-04-15
Brief Title:
A Study of AK104Lenvatinib in Combination With Transarterial Chemoembolization TACE Versus TACE in Participants With IncurableNon-metastatic Hepatocellular Carcinoma
Sponsor:
Akeso
Organization:
Akeso
Study Overview
Official Title:
A Phase III Randomized Double-blinded Multicenter Study of Cadonilimab AK104 Lenvatinib in Combination With Transarterial Chemoembolization TACE Versus TACE in Participants With IncurableNon-metastatic Hepatocellular Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to evaluate cadonilimab AK104 lenvatinib in combination with transarterial chemoembolization TACE versus TACE in participants with incurablenon-metastatic hepatocellular carcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None